ATTR-CM Affects Women, Too – Cleveland Clinic Health Essentials

AI News Q&A (Free Content)

Q1: What is transthyretin amyloid cardiomyopathy (ATTR-CM) and how does it affect the heart?

A1: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that results from the deposition of amyloid fibrils in the heart, specifically caused by the transthyretin protein. These fibrils cause the heart muscle to stiffen, leading to diastolic dysfunction, and eventually heart failure. The condition is historically more recognized in men, but recent findings suggest it affects women as well, although it might be underdiagnosed in them.

Q2: Why might ATTR-CM be underdiagnosed in women?

A2: ATTR-CM may be underdiagnosed in women due to several reasons, including the general underrepresentation of women in cardiology research, which leads to a lack of awareness about how the condition presents in women. Additionally, women with ATTR-CM are often diagnosed later in life and may have overlapping diagnoses such as heart failure with preserved ejection fraction, which can obscure the presence of amyloidosis.

Q3: What recent advancements have been made in diagnosing ATTR-CM using imaging techniques?

A3: Recent advancements in diagnosing ATTR-CM include the use of I-evuzamitide, a novel radiotracer for PET/CT scans. This technique has shown promise in detecting cardiac involvement in amyloidosis, even in its rare forms. Studies have demonstrated its ability to differentiate between those with and without cardiomyopathy by measuring myocardial uptake, providing a more accurate diagnosis of ATTR-CM.

Q4: What are the implications of the underdiagnosis of ATTR-CM in women for treatment and clinical trials?

A4: The underdiagnosis of ATTR-CM in women can lead to delayed treatment and missed therapeutic opportunities. It also affects the recruitment of women in clinical trials, skewing research findings and impacting the development of treatment guidelines. This gap highlights the need for increased awareness and better diagnostic criteria to ensure equitable healthcare.

Q5: How does familial amyloid cardiomyopathy differ from senile systemic amyloidosis?

A5: Familial amyloid cardiomyopathy (FAC) differs from senile systemic amyloidosis (SSA) in that FAC is caused by a genetic mutation leading to the misassembly of transthyretin proteins into amyloid fibrils, whereas SSA is not inherited and typically affects the elderly. FAC leads to rigidity in the heart walls, while SSA primarily affects heart function in the very old, often contributing to their mortality.

Q6: What are some challenges in diagnosing ATTR-CM in its early stages?

A6: Early diagnosis of ATTR-CM is challenging due to the subtlety of initial symptoms and the potential overlap with other cardiac conditions. Standard imaging techniques may not always detect the early amyloid deposits, and symptoms can be nonspecific, leading to misdiagnosis or delayed diagnosis. Enhanced imaging techniques and increased clinical awareness are crucial for early detection.

Q7: What role does gender play in the genetic risk and diagnosis of hereditary ATTR?

A7: In hereditary ATTR, both men and women inherit the genetic mutation at equal rates. However, women are often diagnosed at older ages compared to men with the same genetic risk. This suggests that gender influences how and when amyloidosis is identified, potentially due to differences in clinical presentation and diagnostic biases, which underscores the importance of gender-sensitive approaches in diagnosis.

References:

• Amyloid cardiomyopathy - https://en.wikipedia.org/wiki/Amyloid_cardiomyopathy
• Cleveland Clinic Health Essentials - https://health.clevelandclinic.org/attr-cm-in-women
• Assessment of Cardiac Involvement in Rare Forms of Amyloidosis Using PET/CT with I-Evuzamitide (I-p5+14, AT-01)
• American Heart Month: Are We Missing ATTR-CM in Women? - https://arci.org/american-heart-month-are-we-missing-attr-cm-in-women/